You are here

  • Home
  • Archive
  • Volume 10, Issue 3
  • Delivery of a β2 agonist by metered dose inhaler with a bottle spacer was equivalent to delivery by conventional spacer in young children with acute lower airway obstruction

Article Text

Article menu
Download PDFPDF
Treatment
Delivery of a β2 agonist by metered dose inhaler with a bottle spacer was equivalent to delivery by conventional spacer in young children with acute lower airway obstruction

https://doi.org/10.1136/ebn.10.3.74

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Zar HJ, Streun S, Levin M, et al. Randomised controlled trial of the efficacy of a metered dose inhaler with bottle spacer for bronchodilator treatment in acute lower airway obstruction. Arch Dis Child 2007;92:142–6.OpenUrlAbstract/FREE Full Text

    Q In young children with acute lower airway obstruction, is response to bronchodilator treatment given using a metered dose inhaler (MDI) with a bottle spacer equivalent to that given using a conventional spacer?

    METHODS

    Embedded ImageDesign:

    randomised controlled equivalence trial.

    Embedded ImageAllocation:

    concealed.

    Embedded ImageBlinding:

    blinded ({healthcare providers, data collectors},* and clinical outcome assessors).

    Embedded ImageFollow up period:

    after completion of 3 bronchodilator treatments.

    Embedded ImageSetting:

    a children’s hospital in Cape Town, South Africa.

    Embedded ImagePatients:

    400 children aged 2 months to 5 years (median age 12 mo, 39% boys) who presented with clinical signs of acute lower airway obstruction (expiratory wheeze on auscultation or hyperinflation of the chest) and had cough or difficulty breathing within the previous 5 days. Exclusion criteria were bronchodilator use in the previous 4 hours, underlying cardiac or chronic pulmonary disease (other than asthma), stridor, or …

    View Full Text

    Footnotes

    • ↵* Information provided by author.

    • For correspondence: Professor H Zar, Red Cross War Memorial Children’s Hospital, University of Cape Town, Cape Town, South Africa. hzar{at}ich.uct.ac.za

    • Sources of funding: World Health Organization and Allergy Society of South Africa.